Invivyd Inc (IVVD)
2.40
-0.05
(-2.04%)
USD |
NASDAQ |
May 17, 16:00
2.40
0.00 (0.00%)
After-Hours: 20:00
Invivyd Enterprise Value: 96.97M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 17, 2024 | 96.97M |
May 16, 2024 | 102.94M |
May 15, 2024 | 104.13M |
May 14, 2024 | 100.55M |
May 13, 2024 | 93.39M |
May 10, 2024 | 80.27M |
May 09, 2024 | 99.36M |
May 08, 2024 | 112.48M |
May 07, 2024 | 110.09M |
May 06, 2024 | 92.20M |
May 03, 2024 | 99.36M |
May 02, 2024 | 93.39M |
May 01, 2024 | 99.13M |
April 30, 2024 | 75.28M |
April 29, 2024 | 58.59M |
April 26, 2024 | 66.94M |
April 25, 2024 | 57.40M |
April 24, 2024 | 64.55M |
April 23, 2024 | 81.24M |
April 22, 2024 | 71.71M |
April 19, 2024 | 84.82M |
April 18, 2024 | 90.78M |
April 17, 2024 | 106.28M |
April 16, 2024 | 132.51M |
April 15, 2024 | 145.62M |
Date | Value |
---|---|
April 12, 2024 | 162.31M |
April 11, 2024 | 174.83M |
April 10, 2024 | 169.47M |
April 09, 2024 | 170.66M |
April 08, 2024 | 175.43M |
April 05, 2024 | 204.04M |
April 04, 2024 | 237.42M |
April 03, 2024 | 279.15M |
April 02, 2024 | 264.84M |
April 01, 2024 | 317.30M |
March 28, 2024 | 328.70M |
March 27, 2024 | 276.24M |
March 26, 2024 | 235.71M |
March 25, 2024 | 184.44M |
March 22, 2024 | 319.16M |
March 21, 2024 | 167.75M |
March 20, 2024 | 178.48M |
March 19, 2024 | 193.98M |
March 18, 2024 | 195.17M |
March 15, 2024 | 228.56M |
March 14, 2024 | 234.52M |
March 13, 2024 | 239.29M |
March 12, 2024 | 230.94M |
March 11, 2024 | 241.47M |
March 08, 2024 | 237.90M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-259.55M
Minimum
Dec 28 2022
5.846B
Maximum
Sep 16 2021
369.93M
Average
-76.95M
Median
Enterprise Value Benchmarks
Vanda Pharmaceuticals Inc | -75.22M |
Viking Therapeutics Inc | 6.425B |
Stoke Therapeutics Inc | 545.89M |
180 Life Sciences Corp | 0.4257M |
MAIA Biotechnology Inc | 64.01M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -43.50M |
Total Expenses (Quarterly) | 46.09M |
EPS Diluted (Quarterly) | -0.38 |
Earnings Yield | -77.92% |